Related Experiment Video

Updated: Nov 29, 2025

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.4K

Mineralocorticoid receptor blockade improves pulmonary hypertension and right ventricular function in

Roberto Giagnorio1, Georg Hansmann1

  • 1Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany.

Cardiovascular Diagnosis and Therapy
|November 23, 2020
PubMed

Insights

This study shows that adding spironolactone and hydrochlorothiazide improved a premature infant's chronic lung disease and pulmonary hypertension. Biomarkers and echocardiography confirmed rapid recovery of heart function.

Area of Science:

  • Pediatric Pulmonology
  • Neonatology
  • Cardiology

Background:

  • Bronchopulmonary dysplasia (BPD) is a leading cause of chronic lung disease in infants.
  • Persistent pulmonary hypertension (PH) in BPD significantly elevates mortality risk.
  • Right heart failure is a severe complication associated with BPD and PH.

Observation:

  • A 4-month-old infant, previously preterm, presented with BPD, severe PH, and right heart failure.
  • The infant's clinical status and right ventricular (RV) function were monitored.
  • Blood biomarkers (NT-pro-BNP, troponin T) and echocardiography were utilized for assessment.

Findings:

  • Addition of spironolactone and hydrochlorothiazide to the infant's regimen led to rapid clinical improvement.
  • Significant enhancement in right ventricular function was observed post-treatment.
  • Biomarker levels and echocardiographic data corroborated the positive therapeutic response.

Implications:

  • Spironolactone and hydrochlorothiazide may offer a novel therapeutic approach for infants with BPD and PH.
  • This treatment strategy shows potential for improving outcomes in severe BPD cases.
  • Further research is warranted to explore the efficacy and safety of these diuretics in BPD-PH management.

Keywords:
Pulmonary hypertension (PH)bronchopulmonary dysplasia (BPD)case reporthydrochlorothiazide (HCTZ)spironolactone

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.2K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
331
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
569
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
690
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
446
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
297
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
578